1,427 results on '"Radich, Jerald P."'
Search Results
2. Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients
3. Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study
4. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
5. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
6. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
7. Management of chronic myeloid leukemia in 2023 – common ground and common sense
8. CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries
9. Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation
10. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
11. Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
12. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
13. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
14. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
15. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
16. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
17. AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker
18. MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis
19. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
20. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
21. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.
22. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.
23. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
24. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation
25. Chronic Myeloid Leukemia: Chronic Phase Disease
26. Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia
27. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
28. Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries
29. A graphical, interactive and GPU-enabled workflow to process long-read sequencing data
30. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
31. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
32. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients
33. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
34. The (near) miracle of therapy in chronic myeloid leukaemia
35. Ultrasensitive Chimerism Enhances Measurable Residual Disease Testing Post-Allogeneic Hematopoietic Cell Transplantation
36. Chronic Myelogenous Leukemia, Version 1.2014.
37. Point-of-care BCR::ABL1transcript monitoring using capillary dried blood in chronic myeloid leukemia patients
38. Monitoring efforts in myeloproliferative neoplasms
39. Minimal Residual Disease
40. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
41. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
42. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
43. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
44. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
45. Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
46. Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
47. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
48. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL
49. Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
50. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.